Evidence map›Paper›PMID 40275869›Full record

ArticleRSC advances2025

Ningwei Wang, Xu Yan, Chaofei Ji, Jinlong Hu, Xiangshun Chen, Cong Zhang, Yuzhu Quan, Tao He, Tianci Sun, Yue Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. FeRSC advances · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ningwei WangDepartment of Gastroenterology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Hefei 230001 China yuyuemd@ustc.edu.cn.
Xu YanAnhui Province Key Laboratory of Value-Added Catalytic Conversion and Reaction Engineering, Anhui Province Engineering Research Center of Flexible and Intelligent Materials, School of Chemistry and Chemical Engineering, Hefei University of Technology Hefei 230001 China taohe@hfut.edu.cn suntianci@mail.hfut.edu.cn.
Chaofei JiDepartment of Radiology, Anhui No. 2 Provincial People's Hospital Hefei 230001 China.
Jinlong HuDepartment of General Surgery, Anhui No. 2 Provincial People's Hospital Hefei 230001 China.
Xiangshun ChenAnhui Province Key Laboratory of Value-Added Catalytic Conversion and Reaction Engineering, Anhui Province Engineering Research Center of Flexible and Intelligent Materials, School of Chemistry and Chemical Engineering, Hefei University of Technology Hefei 230001 China taohe@hfut.edu.cn suntianci@mail.hfut.edu.cn.
Cong ZhangDepartment of Gastroenterology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Hefei 230001 China yuyuemd@ustc.edu.cn.
Yuzhu QuanChangchun GeneScience Pharmaceutical Co., Ltd. Xuhui District Shanghai 200030 China.
Tao HeAnhui Province Key Laboratory of Value-Added Catalytic Conversion and Reaction Engineering, Anhui Province Engineering Research Center of Flexible and Intelligent Materials, School of Chemistry and Chemical Engineering, Hefei University of Technology Hefei 230001 China taohe@hfut.edu.cn suntianci@mail.hfut.edu.cn.ORCID https://orcid.org/0009-0002-1205-5327
Tianci SunAnhui Province Key Laboratory of Value-Added Catalytic Conversion and Reaction Engineering, Anhui Province Engineering Research Center of Flexible and Intelligent Materials, School of Chemistry and Chemical Engineering, Hefei University of Technology Hefei 230001 China taohe@hfut.edu.cn suntianci@mail.hfut.edu.cn.
Yue YuDepartment of Gastroenterology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Hefei 230001 China yuyuemd@ustc.edu.cn.ORCID https://orcid.org/0000-0002-3617-2037

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a malignancy with a poor prognosis and high mortality. Survival outcomes remain very poor despite significant advances in molecular diagnostics and therapeutics in clinical practice. Surgical resection is the only potentially curative treatment, but the tumor is often diagnosed at an advanced stage, and most cancers recur after surgery. Treatments other than surgery, including chemotherapy and immunotherapy, still offer disappointing results. Multidisciplinary treatment approaches through appropriate carriers have provided new solutions for improving the prognosis of pancreatic cancer. Herein, we reported an

Identifiers

PMID40275869
PMCPMC12019213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.